Thubilux Pharma SpA has received a structured loan of US$2.7 million from a leading Italian bank

Tubilux Pharma SpA has successfully raised funds through a structured loan from Cassa Depositi e Prestiti SpA and Banca Intesa San Paolo SpA to support an investment plan for a new production facility which has all the FDA requirements to enter the USA market.

Tubilux Pharma is a leading, privately-held ophthalmic and pharmaceuticals company that develops and markets a range of proprietary, over-the-counter, and branded generic products, with distribution in approximately 30 countries. The firm's customers are large multinational pharmaceutical companies that outsource their production of ophthalmic products to specialized manufactures through medium-term supply contracts (3-5 years).

Oaklins' team in Italy advised Thubilux Pharma SpA in the structuring, negotiation and closing of a long-term debt financing from a leading Italian bank, backed by Cassa Depositi e Prestiti.